Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis - PubMed
8 hours ago
- #Myasthenia Gravis
- #Serum Albumin
- #FcRn Inhibitors
- Efgartigimod and rozanolixizumab are both neonatal Fc receptor (FcRn) inhibitors used for generalized myasthenia gravis but have different molecular structures.
- The study found that both drugs similarly reduced serum IgG levels in patients, with no significant difference between them.
- Efgartigimod increased serum albumin levels in most cases (94%), while rozanolixizumab decreased serum albumin levels in all cases (100%).
- There was a significant difference in the change in serum albumin levels between the two treatment groups.
- The opposing effects on albumin, despite similar IgG reduction, suggest distinct interactions with the FcRn-albumin recycling pathway.